MiMedx Group (MDXG) to Release Earnings on Wednesday

MiMedx Group (NASDAQ:MDXG) is expected to be issuing its Q2 2026 results after the market closes on Wednesday, July 29th. Analysts expect the company to post earnings of ($0.0495) per share and revenue of $63.46 million for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, July 29, 2026 at 4:30 PM ET.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings data on Wednesday, April 29th. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.02. MiMedx Group had a net margin of 7.88% and a return on equity of 21.03%. The company had revenue of $58.99 million for the quarter, compared to analyst estimates of $65.80 million. On average, analysts expect MiMedx Group to post $-0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MiMedx Group Price Performance

NASDAQ MDXG opened at $4.26 on Tuesday. MiMedx Group has a 52-week low of $3.03 and a 52-week high of $7.99. The firm’s 50 day moving average price is $3.88 and its 200-day moving average price is $4.28. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.81 and a current ratio of 5.39. The company has a market cap of $634.53 million, a PE ratio of 21.30 and a beta of 1.45.

Hedge Funds Weigh In On MiMedx Group

Institutional investors have recently made changes to their positions in the company. Kemnay Advisory Services Inc. acquired a new position in shares of MiMedx Group in the 4th quarter valued at $48,000. Headlands Technologies LLC acquired a new stake in MiMedx Group during the second quarter valued at $72,000. Jain Global LLC purchased a new position in MiMedx Group in the fourth quarter valued at $73,000. Virtu Financial LLC purchased a new position in MiMedx Group in the fourth quarter valued at $78,000. Finally, Osaic Holdings Inc. raised its position in shares of MiMedx Group by 57.2% in the second quarter. Osaic Holdings Inc. now owns 12,943 shares of the company’s stock worth $79,000 after acquiring an additional 4,708 shares during the period. 79.15% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently commented on MDXG shares. Wall Street Zen lowered shares of MiMedx Group from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Craig Hallum cut their price objective on shares of MiMedx Group from $10.00 to $7.00 and set a “buy” rating on the stock in a research note on Friday, April 17th. Citizens Jmp reduced their target price on shares of MiMedx Group from $7.00 to $6.00 and set a “market outperform” rating for the company in a report on Thursday, April 30th. Finally, Weiss Ratings lowered MiMedx Group from a “sell (d+)” rating to a “sell (d)” rating in a research note on Monday, May 18th. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $8.50.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.